Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | IDE | P14735 | 2/20 | 0.52 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 8/20 | 0.35 |
| ▸ | CA1 | P00915 | 8/20 | 0.35 |
| ▸ | CA2 | P00918 | 8/20 | 0.35 |
| ▸ | CA9 | Q16790 | 8/20 | 0.35 |
| ▸ | HLCS | P50747 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3423752 | 0.86 | TDP1 (0.58) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL30107625 | 0.84 | TDP1 (0.74) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL7169914 | 0.84 | TDP1 (0.50) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL18386701 | 0.81 | TDP1 (0.58) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL14617993 | 0.81 | TDP1 (0.47) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL31297012 | 0.81 | TDP1 (0.52) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL19751635 | 0.79 | TDP1 (0.58) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL4967996 | 0.79 | TDP1 (0.58) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL19751767 | 0.79 | TDP1 (0.58) | TDP1ABL1IDERIN1MEN1 | |
| SCHEMBL12642068 | 0.78 | TDP1 (0.56) | TDP1ABL1IDERIN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139075-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | ROCHE DIAGNOSTICS OPERATIONS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-3562841-B1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | HOFFMANN LA ROCHE (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-12559573-B2 | Biotin-specific monoclonal antibody and use thereof | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4685490-A2 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| EP-4653868-A2 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2025-11-26 | — | — | EP | disclosed |
| EP-4647769-A2 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2025-11-12 | — | — | EP | disclosed |
| US-20250306016-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | ROCHE DIAGNOSTICS OPERATIONS INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-3562842-B1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | HOFFMANN LA ROCHE (CH) | 2025-10-01 | — | — | EP | disclosed |
| EP-3562845-B1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | HOFFMANN LA ROCHE (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-12360108-B2 | Biotin-specific monoclonal antibody and use thereof | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2025-07-15 | — | — | US | disclosed |
| US-20240377388-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-12025613-B2 | Biotin-specific monoclonal antibody and use thereof | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20220106408-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | ROCHE DIAGNOSTICS GMBH (DE) | 2022-04-07 | — | — | US | disclosed |
| US-20220107310-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220107309-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | ROCHE DIAGNOSTICS GMBH (DE) | 2022-04-07 | — | — | US | disclosed |
| US-20190324024-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190324024-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | BTD, IGLV6-57, VSIR | TDP1 4750/4885ABL1 3134/4885IDE 553/4885 |
| US-20220106408-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | BTD, IGLV6-57, VSIR | TDP1 4750/4885ABL1 3134/4885IDE 553/4885 |
| US-20220107310-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | BTD, IGLV6-57, VSIR | TDP1 4750/4885ABL1 3134/4885IDE 553/4885 |
| US-20250306016-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | BTD, IGLV6-57, VSIR | TDP1 4750/4885ABL1 3134/4885IDE 553/4885 |
| US-12025613-B2 | Biotin-specific monoclonal antibody and use thereof | BTD, IGLV6-57, VIM | TDP1 4556/4885ABL1 1338/4885IDE 522/4885 |
| US-20220107309-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | BTD, IGLV6-57, VSIR | TDP1 4750/4885ABL1 3134/4885IDE 553/4885 |
| US-12559573-B2 | Biotin-specific monoclonal antibody and use thereof | IGLV6-57, LY96, BTD | TDP1 4725/4885ABL1 1952/4885IDE 1884/4885 |
| US-20260139075-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | CD22, LY96, F13B | TDP1 4799/4885ABL1 2440/4885IDE 1707/4885 |
| US-20240377388-A1 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | BTD, IGLV6-57, VSIR | TDP1 4750/4885ABL1 3134/4885IDE 553/4885 |
| US-12360108-B2 | Biotin-specific monoclonal antibody and use thereof | BTD, IGLV6-57, VIM | TDP1 4556/4885ABL1 1338/4885IDE 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.